How to manage rheumatic patients during the coronavirus pandemic

Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology*
  • Disease Susceptibility
  • Humans
  • Hydroxychloroquine / adverse effects
  • Hydroxychloroquine / therapeutic use
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Pandemics*
  • Patient Care Management / methods
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / epidemiology*
  • Rheumatic Diseases / complications*
  • Rheumatic Diseases / therapy*
  • Risk Factors
  • SARS-CoV-2
  • Telemedicine

Substances

  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Hydroxychloroquine